A Prospective Study of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 \& PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
View:
• Patients with confirmed pathological diagnosis of aggressive PTCL
• Age 18-65 years old
• Achieving CR or PR after first-line therapy
Locations
Other Locations
China
Beijing Cancer Hospital
RECRUITING
Beijing
Contact Information
Primary
Jun Zhu, Dr.
zhu-jun2017@outlook.com
+86-13910333346
Time Frame
Start Date: 2020-11-30
Estimated Completion Date: 2025-11-30
Participants
Target number of participants: 60
Treatments
ASCT group
patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy
Observation group
patients who achieved CR or PR after 6-8 cycles first-line therapy finish their therapy and go into follow-up
Related Therapeutic Areas
Sponsors
Leads: Peking University